Abstract
We evaluated relative vaccine effectiveness (rVE) of 4- vs. 3-dose mRNA-1273 against SARS-CoV-2 infection, and COVID-19 hospitalization and death in immunocompetent adults aged ≥50 years at Kaiser Permanente Southern California. We included 178,492 individuals who received a fourth dose of mRNA-1273, and 178,492 randomly selected 3-dose recipients who were matched to 4-dose recipients by age, sex, race/ethnicity, and third dose date. Adjusted 4- vs. 3-dose rVE against SARS-CoV-2 infection, COVID-19 hospitalization, and COVID-19 hospitalization death were 25.9 % (23.5 %, 28.2 %), 67.3 % (58.7 %, 74.1 %), and 72.5 % (-35.9 %, 95.2 %), respectively. Adjusted rVE against SARS-CoV-2 infection ranged between 19.8 % and 39.1 % across subgroups. Adjusted rVE against SARS-CoV-2 infection and COVID-19 hospitalization decreased 2–4 months after the fourth dose. Four mRNA-1273 doses provided significant protection against COVID-19 outcomes compared with 3 doses, consistent in various subgroups of demographic and clinical characteristics, although rVE varied and waned over time.
Keywords: COVID-19, Infectious disease medicine, Virology, Epidemiology
1. Introduction
As of November 2022, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in >101 million infections and >1 million deaths in the United States [1]. Individuals aged ≥50 years are at a higher risk of severe COVID-19 disease [2]. In March 2022, the Food and Drug Administration authorized a second monovalent mRNA-based booster dose, 4 months after dose 3 for individuals at high risk of severe disease, including immunocompetent adults aged ≥50 years [3].
Studies have reported on the significant protection of 4 doses (vs. unvaccinated) of mRNA vaccines against SARS-CoV-2 infection, and COVID-19 hospitalization and death [4]. Although some studies have evaluated the 4- vs. 3-dose relative vaccine effectiveness (rVE) of mRNA vaccines [5], [6], data are lacking for mRNA-1273 specifically among the general US population aged ≥50 years and by subgroups. Additionally, while the uptake of the primary monovalent series in the older US population is high (>94 % for ≥ 65 years), booster uptake is low (monovalent second booster, <40 % for ≥50 years; bivalent booster, 39 % for ≥65 years) [7]. Consequently, better understanding of the 4- vs. 3-dose rVE of mRNA-1273 is of public health importance. We evaluated rVE of 4 doses of mRNA-1273 compared to 3 doses against SARS-CoV-2 infection and severe COVID-19 disease in immunocompetent individuals aged ≥50 years by demographic and clinical subgroups during the omicron period.
2. Methods
Study setting is described in detail in our prior publications [8]. Immunocompetent Kaiser Permanente Southern California (KPSC) members aged ≥50 years were included (Supplementary Fig. 1). Comprehensive electronic health record (EHR) data used for this study included demographics, immunizations, ambulatory visits, hospitalizations, and pharmacy records.
The study included eligible individuals who received a fourth dose of mRNA-1273 ≥120 days after the third dose (4-dose group), and eligible individuals who received 3 doses of mRNA-1273 (3-dose group) as of the index date. Three-dose recipients were randomly selected and 1:1 matched to 4-dose recipients by age, sex, race/ethnicity, and third dose date. Index date was defined as the date of the fourth dose for the 4-dose recipients; the same index date was assigned to their matched 3-dose vaccinated counterparts. Fourth doses were accrued between 03/29/2022 and 07/31/2022, with follow-up through 08/31/2022. Those who received a COVID-19 vaccine other than mRNA-1273 prior to index date; received a second, third, or fourth dose of mRNA-1273 <24 days, <150 days, or <120 days from their previous dose, respectively; or received any COVID-19 vaccine, died, or had a COVID-19 outcome <14 days after the index date were excluded.
Exposure of interest was 3 or 4 doses of monovalent mRNA-1273. Outcomes were SARS-CoV-2 infection, COVID-19 hospitalization, and COVID-19 hospital death [8]. We identified symptomatic vs. asymptomatic SARS-CoV-2 infections using natural language processing [9]. We considered SARS-CoV-2 infection incident if there was no COVID-19 diagnosis code or SARS-CoV-2 positive test in the 90 days prior. Individuals were followed for outcomes from 14 days after the index date until end of follow-up (08/31/2022), termination of KPSC membership, death, or receipt of an additional COVID-19 vaccine, whichever occurred first. Individuals in the 3-dose group who received an eligible fourth dose during follow-up were censored and started contributing 4-dose person-time, 14 days after their fourth dose.
We described characteristics of the 3-dose and 4-dose groups. Covariates included in the multivariable models, along with matching variables, were selected based on scientific relevance or absolute standardized differences >0.1. Incidence rates (IR) and cumulative incidence were calculated. Hazard ratios (HR) were estimated using Cox proportional hazards regression. rVE (%) was calculated as (1 – HR) × 100 when HR was ≤1, and ([1/HR] – 1) × 100 when HR was >1. All statistical analyses were conducted using SAS software version 9.4, Cary, USA. This study was approved by the KPSC Institutional Review Board.
3. Results
Our study included 178,492 immunocompetent adults aged ≥50 years who received 4 doses of mRNA-1273, and 178,492 matched counterparts who received 3 doses (Supplementary Fig. 1). The cohort was 55 % female and 44 % non-Hispanic White, with a mean age of 69 years (standard deviation, 10) (Table 1 ). Baseline demographic and clinical characteristics were comparable between groups.
Table 1.
Baseline characteristics of 4-dose and 3-dose mRNA-1273 vaccinated immunocompetent adults aged ≥50 years, Kaiser Permanente Southern California.
| 4-dose Vaccinated | 3-dose Vaccinated | Total | p-value | ASD | |
|---|---|---|---|---|---|
| N = 178,492 | N = 178,492 | N = 356,984 | |||
| Age at index date, years | <0.01 | 0.02 | |||
| Mean (standard deviation) | 68.84 (9.9) | 68.65 (10.1) | 68.75 (10.0) | ||
| Median (quartile 1, quartile 3) | 69 (62, 76) | 69 (61, 76) | 69 (61, 76) | ||
| Minimum, Maximum | 50, 107 | 50, 109 | 50, 109 | ||
| Age at index date, years, n (%) | N/A | N/A | |||
| 50–64 | 61,003 (34.2) | 61,003 (34.2) | 1220,06 (34.2) | ||
| 65–74 | 66,297 (37.1) | 66,297 (37.1) | 132,594 (37.1) | ||
| ≥75 | 51,192 (28.7) | 51,192 (28.7) | 102,384 (28.7) | ||
| Sex, n (%) | N/A | N/A | |||
| Female | 97,344 (54.5) | 97,344 (54.5) | 194,688 (54.5) | ||
| Male | 81,148 (45.5) | 81,148 (45.5) | 162,296 (45.5) | ||
| Race/Ethnicity, n (%) | N/A | N/A | |||
| Non-Hispanic White | 77,714 (43.5) | 77,714 (43.5) | 155,428 (43.5) | ||
| Non-Hispanic Black | 16,243 (9.1) | 16,243 (9.1) | 32,486 (9.1) | ||
| Hispanic | 48,599 (27.2) | 48,599 (27.2) | 97,198 (27.2) | ||
| Non-Hispanic Asian | 27,486 (15.4) | 27,486 (15.4) | 54,972 (15.4) | ||
| Other/Unknown | 8,450 (4.7) | 8,450 (4.7) | 16,900 (4.7) | ||
| Body mass indexa, kg/m2, n (%) | <0.01 | 0.03 | |||
| <18.5 | 2,102 (1.2) | 2,240 (1.3) | 4,342 (1.2) | ||
| 18.5 - <25 | 45,425 (25.4) | 44,489 (24.9) | 89,914 (25.2) | ||
| 25 - <30 | 60,132 (33.7) | 59,994 (33.6) | 120,126 (33.7) | ||
| 30 - <35 | 35,066 (19.6) | 35,032 (19.6) | 70,098 (19.6) | ||
| 35 - <40 | 14,944 (8.4) | 14,780 (8.3) | 29,724 (8.3) | ||
| 40 - <45 | 5,656 (3.2) | 5,535 (3.1) | 11,191 (3.1) | ||
| ≥45 | 2,986 (1.7) | 2,882 (1.6) | 5,868 (1.6) | ||
| Unknown | 12,181 (6.8) | 13,540 (7.6) | 25,721 (7.2) | ||
| Smokinga, n (%) | <0.01 | 0.03 | |||
| No | 130,108 (72.9) | 128,580 (72.0) | 258,688 (72.5) | ||
| Yes | 40,760 (22.8) | 41,072 (23.0) | 81,832 (22.9) | ||
| Unknown | 7,624 (4.3) | 8,840 (5.0) | 16,464 (4.6) | ||
| Charlson comorbidity scoreb, n (%) | <0.01 | 0.02 | |||
| 0 | 81,815 (45.8) | 83,103 (46.6) | 164,918 (46.2) | ||
| 1 | 36,750 (20.6) | 35,813 (20.1) | 72,563 (20.3) | ||
| ≥2 | 59,927 (33.6) | 59,576 (33.4) | 119,503 (33.5) | ||
| Frailty indexb | 0.22 | 0.01 | |||
| Mean (standard deviation) | 0.1 (0) | 0.13 (0) | 0.13 (0) | ||
| Median (quartile 1, quartile 3) | 0.1 (0.1, 0.1) | 0.1 (0.1, 0.1) | 0.1 (0.1, 0.1) | ||
| Minimum, Maximum | 0, 0.4 | 0, 0.4 | 0, 0.4 | ||
| Frailty indexb, n (%) | <0.01 | 0.01 | |||
| Quartile 1 | 44,527 (24.9) | 44,822 (25.1) | 89,349 (25.0) | ||
| Quartile 2 | 44,207 (24.8) | 44,784 (25.1) | 88,991 (24.9) | ||
| Quartile 3 | 45,239 (25.3) | 44,158 (24.7) | 89,397 (25.0) | ||
| Quartile 4, most frail | 44,519 (24.9) | 44,728 (25.1) | 89,247 (25.0) | ||
| Antiviral therapyc | <0.01 | 0.07 | |||
| No | 175,016 (98.1 %) | 176,516 (98.9 %) | 351,532 (98.5 %) | ||
| Yes | 3,476 (1.9 %) | 1,976 (1.1 %) | 5,452 (1.5 %) | ||
| Chronic diseasesb, n (%) | |||||
| Kidney disease | 23,127 (13.0) | 23,558 (13.2) | 46,685 (13.1) | 0.03 | 0.01 |
| Heart disease | 11,453 (6.4) | 12,088 (6.8) | 23,541 (6.6) | <0.01 | 0.01 |
| Lung disease | 22,529 (12.6) | 22,115 (12.4) | 44,644 (12.5) | 0.04 | 0.01 |
| Liver disease | 7,734 (4.3) | 7,506 (4.2) | 15,240 (4.3) | 0.06 | 0.01 |
| Diabetes | 47,887 (26.8) | 47,815 (26.8) | 95,702 (26.8) | 0.79 | <0.01 |
| Autoimmune conditionsb, n (%) | 6,392 (3.6) | 6,358 (3.6) | 12,750 (3.6) | 0.76 | <0.01 |
| Rheumatoid arthritis, n | 2,185 | 2,329 | 4,514 | ||
| Inflammatory bowel disease, n | 1,111 | 1,061 | 2,172 | ||
| Psoriasis and psoriatic arthritis, n | 2,891 | 2,780 | 5,671 | ||
| Multiple sclerosis, n | 338 | 313 | 651 | ||
| Systemic lupus erythematosus, n | 326 | 295 | 621 | ||
| History of SARS-CoV-2 infectionc, n (%) | 20,583 (11.5) | 24,215 (13.6) | 44,798 (12.5) | <0.01 | 0.06 |
| ≤6 months since prior infection, n | 8,948 | 11,098 | 20,046 | ||
| 7–12 months since prior infection, n | 1,974 | 2,062 | 4,036 | ||
| >12 months since prior infection, n | 9,661 | 11,055 | 20,716 | ||
| History of SARS-CoV-2 molecular testd, n (%) | 110,631 (62.0) | 108,979 (61.1) | 219,610 (61.5) | <0.01 | 0.02 |
| Number of outpatient and virtual visitsb, n (%) | <0.01 | 0.07 | |||
| 0 | 3,491 (2.0) | 4,489 (2.5) | 7,980 (2.2) | ||
| 1–4 | 32,255 (18.1) | 35,774 (20.0) | 68,029 (19.1) | ||
| 5–10 | 59,159 (33.1) | 58,980 (33.0) | 118,139 (33.1) | ||
| ≥11 | 83,587 (46.8) | 79,249 (44.4) | 162,836 (45.6) | ||
| Number of Emergency Department visitsb, n (%) | <0.01 | 0.02 | |||
| 0 | 148,578 (83.2) | 147,160 (82.4) | 295,738 (82.8) | ||
| 1 | 21,361 (12.0) | 21,989 (12.3) | 43,350 (12.1) | ||
| ≥2 | 8,553 (4.8) | 9,343 (5.2) | 17,896 (5.0) | ||
| Number of hospitalizationsb, n (%) | <0.01 | 0.03 | |||
| 0 | 169,985 (95.2) | 169,025 (94.7) | 339,010 (95.0) | ||
| 1 | 6,619 (3.7) | 7,119 (4.0) | 13,738 (3.8) | ||
| ≥2 | 1,888 (1.1) | 2,348 (1.3) | 4,236 (1.2) | ||
| Preventive careb, n (%) | 170,123 (95.3) | 166,528 (93.3) | 336,651 (94.3) | <0.01 | 0.09 |
| Medicaid, n (%) | 8,935 (5.0) | 9,772 (5.5) | 18,707 (5.2) | <0.01 | 0.02 |
| Neighborhood median household income, n (%) | <0.01 | 0.04 | |||
| < $40,000 | 5,057 (2.8) | 5,583 (3.1) | 10,640 (3.0) | ||
| $40,000-$59,999 | 26,565 (14.9) | 28,136 (15.8) | 54,701 (15.3) | ||
| $60,000-$79,999 | 37,349 (20.9) | 38,238 (21.4) | 75,587 (21.2) | ||
| $80,000+ | 109,431 (61.3) | 106,395 (59.6) | 215,826 (60.5) | ||
| Unknown | 90 (0.1) | 140 (0.1) | 230 (0.1) | ||
| KPSC physician/employee, n (%) | 5,684 (3.2) | 6,146 (3.4) | 11,830 (3.3) | <0.01 | 0.01 |
| Medical center areae | <0.01 | 0.10 | |||
| Concomitant vaccinationf, n (%) | 4,615 (2.6) | N/A | N/A | N/A | N/A |
| Days between 3rd dose and index date | 0.29 | <0.01 | |||
| Mean (standard deviation) | 181.7 (32.4) | 181.6 (32.4) | 181.6 (32.4) | ||
| Median (quartile 1, quartile 3) | 175 (158, 203) | 175 (158, 202) | 175 (158, 202) | ||
| Minimum, Maximum | 120, 282 | 115, 282 | 115, 282 | ||
| Days between 3rd dose and index date, n (%) | 0.67 | <0.01 | |||
| ≤150 days | 27,034 (15.1) | 27,202 (15.2) | 54,236 (15.2) | ||
| 151–210 days | 117,007 (65.6) | 116,781 (65.4) | 233,788 (65.5) | ||
| ≥211 days | 34,451 (19.3) | 34,509 (19.3) | 68,960 (19.3) | ||
| Month of index date, n (%) | N/A | N/A | |||
| March 2022 | 3,007 (1.7) | 3,007 (1.7) | 6,014 (1.7) | ||
| April 2022 | 67,041 (37.6) | 67,041 (37.6) | 134,082 (37.6) | ||
| May 2022 | 48,926 (27.4) | 48,926 (27.4) | 97,852 (27.4) | ||
| June 2022 | 32,482 (18.2) | 32,482 (18.2) | 64,964 (18.2) | ||
| July 2022 | 27,036 (15.1) | 27,036 (15.1) | 54,072 (15.1) | ||
Abbreviations: N/A = not applicable; ASD = absolute standardized difference.
Defined in the two years prior to index date.
Defined in the one year prior to index date.
Received between index date and end of follow-up; includes nirmatrelvir/ritonavir, molnupiravir, and remdesivir.
Defined based on all available medical records from March 1, 2020 to index date.
Frequency and percent for the 19 medical center areas not shown.
Among subjects with concomitant vaccines received with the fourth dose: zoster (59.1 %), Tdap (30.9 %), pneumococcal vaccine (17.9 %), influenza vaccine (3.7 %), and other vaccine (2.7 %).
The IR per 1,000 person-years was higher in the 3-dose group vs. the 4-dose group for SARS-CoV-2 infection (322.4 [95 % CI: 314.9, 330.2]) vs. 248.5 [243.8, 253.2]) and COVID-19 hospitalization (8.5 [7.4, 9.8] vs. 3.0 [2.6, 3.6]) (Table 2 ). Cumulative incidence of all outcomes was consistently higher in the 3-dose group vs. the 4-dose group (p <0.0001, log-rank test) (Fig. 1 A, 1B, and 1C). Adjusted 4- vs. 3-dose rVE against SARS-CoV-2 infection, COVID-19 hospitalization, and COVID-19 hospital death were 25.9 % (23.5 %, 28.2 %), 67.3 % (58.7 %, 74.1 %), and 72.5 % (-35.9 %, 95.2 %), respectively (Table 2). Adjusted rVE against SARS-CoV-2 infection was higher (27.2 % [24.8 %, 29.6 %]) for symptomatic infection compared to asymptomatic infection (8.8 % [-2.1 %, 18.5 %]) and ranged between 19.8 % and 39.1 % across subgroups (Table 2, Supplementary Fig. 2 A). Adjusted rVE against SARS-CoV-2 infection and COVID-19 hospitalization in the first 2 months after the fourth dose was 31.7 % (29.1 %, 34.3 %) and 70.3 % (60.2 %, 77.8%) but decreased to 12.8% (7.3%, 18.0 %) and 58.4 % (36.7 %, 72.7 %) 2–4 months after the fourth dose, respectively (Table 3 , Supplementary Fig. 2 B). The median follow-up time was 1.08 months (interquartile range [IQR] 0.36–2.33 months) and 3.06 months (IQR 2.04–3.94 months) for the 3-dose and 4-dose groups, respectively. A total of 78,154 (44 %) individuals originally in the 3-dose group who received a fourth dose of mRNA-1273 during the vaccination accrual period (03/29/2022 – 07/31/2022) and met the inclusion criteria for the 4-dose group began to contribute 4-dose person-time 14 days after the fourth dose.
Table 2.
Incidence rate and adjusted relative vaccine effectiveness of 4 versus 3 doses of mRNA-1273 against SARS-CoV-2 infection, COVID-19 hospitalization, and COVID-19 hospital death among immunocompetent adults aged ≥ 50 years, overall and by subgroups, Kaiser Permanente Southern California.
|
4-dose Vaccinated |
3-dose Vaccinated |
Adjustedarelative vaccine effectiveness % (95 % CI) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Outcomes | N | Number of cases | Number of person years |
Incidence per 1000 person-years (95 % CI) |
N | Number of cases | Number of person years |
Incidence per 1000 person-years (95 % CI) |
|
| Overall | |||||||||
| SARS-CoV-2 infectionb | 178,492 | 10,765 | 43,323.4 | 248.5 (243.8–253.2) | 178,492 | 6,804 | 21,103.1 | 322.4 (314.9–330.2) | 25.9 (23.5–28.2) |
| COVID-19 hospitalizationc | 178,492 | 135 | 44,695.9 | 3.0 (2.6–3.6) | 178,492 | 186 | 21,906.2 | 8.5 (7.3–9.8) | 67.3 (58.7–74.1) |
| COVID-19 hospital deathd | 178,492 | 2 | 44,712.2 | 0.04 (0.01–0.2) | 178,492 | 4 | 21,926.8 | 0.2 (0.1–0.5) | 72.5 (-35.9–95.2) |
| Subgroups (SARS-CoV-2 infectionb) | |||||||||
| Symptomse | |||||||||
| Asymptomatic | 178,492 | 938 | 43,323.4 | 21.7 (20.3–23.1) | 178,492 | 500 | 21,103.1 | 23.7 (21.7–25.7) | 8.8 (-2.1–18.5) |
| Symptomatic | 178,492 | 9,827 | 43,323.4 | 226.8 (222.4–231.4) | 178,492 | 6,304 | 21,103.1 | 298.7 (291.4–306.2) | 27.2 (24.8–29.6) |
| Age at index date, years | |||||||||
| 50–64 | 61,003 | 3,978 | 13,599.0 | 292.5 (283.6–301.8) | 61,003 | 2,970 | 7,694.4 | 386.0 (372.4–400.1) | 27.2 (23.5–30.6) |
| 65–74 | 66,297 | 4,106 | 16,568.6 | 247.8 (240.35–255.5) | 66,297 | 2,222 | 7,594.1 | 292.6 (280.7–305.0) | 19.8 (15.4–24.1) |
| ≥75 | 51,192 | 2,681 | 13,155.8 | 203.8 (196.2–211.7) | 51,192 | 1,612 | 5,814.6 | 277.2 (264.0–291.1) | 32.3 (27.7–36.6) |
| Sex | |||||||||
| Female | 97,344 | 5,707 | 23,498.3 | 242.9 (236.7–249.3) | 97,344 | 3,755 | 11,341.4 | 331.1 (320.7–341.9) | 28.9 (25.8–31.9) |
| Male | 81,148 | 5,058 | 19,825.1 | 255.1 (248.2–262.3) | 81,148 | 3,049 | 9,761.8 | 312.3 (301.5–323.6) | 22.1 (18.4–25.7) |
| Race/Ethnicityf | |||||||||
| Non-Hispanic White | 77,714 | 4,788 | 19,588.5 | 244.4 (237.6–251.5) | 77,714 | 2,653 | 8,982.3 | 295.4 (284.3–306.8) | 21.5 (17.5–25.3) |
| Non-Hispanic Black | 16,243 | 835 | 3,930.7 | 212.4 (198.5–227.3) | 16,243 | 606 | 1,962.5 | 308.8 (285.2–334.4) | 32.9 (25.2–39.8) |
| Hispanic | 48,599 | 3,046 | 11,089.2 | 274.7 (265.1–284.6) | 48,599 | 2,230 | 6,039.3 | 369.3 (354.2–384.9) | 28.9 (24.7–32.8) |
| Non-Hispanic Asian | 27,486 | 1,674 | 6,708.4 | 249.5 (237.9–261.8) | 27,486 | 992 | 3,070.8 | 323.0 (303.6–343.8) | 25.9 (19.5–31.7) |
| History of SARS-CoV-2 infectionf | |||||||||
| No | 157,909 | 10,172 | 38,826.7 | 262.0 (256.9–267.1) | 154,277 | 6,231 | 18,059.9 | 345.0 (336.6–353.7) | 25.3 (22.8–27.7) |
| Yesg | 20,583 | 593 | 4,496.7 | 131.9 (121.7–142.9) | 24,215 | 573 | 3,043.2 | 188.3 (173.5–204.4) | 34.8 (26.5–42.1) |
| Chronic diseases | |||||||||
| Kidney disease | 23,127 | 1,336 | 5,761.7 | 231.9 (219.8–244.7) | 23,558 | 830 | 2,734.7 | 303.5 (283.6–324.9) | 28.4 (21.6–34.6) |
| Heart diseasef | 11,453 | 693 | 2,806.4 | 247.0 (229.2–266.0) | 12,088 | 503 | 1,430.8 | 351.6 (322.1–383.7) | 32.9 (24.4–40.5) |
| Lung disease | 22,529 | 1,531 | 5,563.6 | 275.2 (261.7–289.3) | 22,115 | 1,020 | 2,529.9 | 403.2 (379.2–428.7) | 35.0 (29.3–40.2) |
| Liver diseasef | 7,734 | 492 | 1,878.4 | 261.9 (239.8–286.1) | 7,506 | 362 | 870.7 | 415.7 (375.1–460.9) | 39.1 (29.8–47.1) |
| Diabetes | 47,887 | 2,890 | 11,581.5 | 249.5 (240.6–258.8) | 47,815 | 2,011 | 5,640.6 | 356.5 (341.3–372.5) | 34.1 (30.1–37.9) |
| Autoimmune conditionsf | 6,392 | 408 | 1,587.9 | 256.9 (233.2–283.1) | 6,358 | 238 | 726.8 | 327.5 (288.4–371.9) | 25.6 (12.1–37.0) |
| Frail individuals,h ages ≥ 65 years | 37,299 | 2,261 | 9,352.5 | 241.8 (232.0–251.9) | 37,962 | 1,472 | 4,350.7 | 338.3 (321.5–356.1) | 32.5 (27.7–37.0) |
When the hazard ratio or its 95 % CI was >1, the rVE or its 95% CI was transformed as ([1/hazard ratio] – 1) × 100.
Abbreviations: CI = confidence interval; N/A = not applicable; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
Adjusted for covariates age, sex, race/ethnicity, index date (in months), time between third dose and index date, history of SARS-CoV-2 infection, and medical center area.
SARS-CoV-2 infection was defined as a positive molecular/antigen test or a COVID-19 diagnosis code for both symptomatic and asymptomatic cases.
COVID-19 hospitalization was defined as hospitalization with a SARS-CoV-2 positive test or a COVID-19 diagnosis, or a hospitalization occurring ≤7 days after a SARS-CoV-2 positive test and confirmed by pre-determined criteria or manual chart review [8].
Age and medical center area were removed from adjustment set due to lack of model convergence.
Symptoms were identified by computerized natural language processing algorithm developed through an iterative process to identify 12 common COVID-19-related symptoms (fever, cough, headache, fatigue, dyspnea, chills, sore throat, myalgia, anosmia, diarrhea, vomiting/nausea, and abdominal pain) in the 14 days prior to 7 days after the infection date among individuals with a positive SARS-CoV-2 molecular/antigen test or a COVID-19 diagnosis.
Medical center area was removed from adjustment set due to lack of model convergence.
Adjusted for time since prior SARS-CoV-2 infection.
Individuals in the fourth quartile of the frailty index were defined as frail.
Fig. 1.
Cumulative incidence estimates of SARS-CoV-2 outcomes in 4-dose and 3-dose mRNA-1273 vaccinated immunocompetent adults aged ≥50 years, Kaiser Permanente Southern California. COVID-19 = Coronavirus disease 2019; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
Table 3.
Incidence rate and adjusted relative vaccine effectiveness of 4 versus 3 doses of mRNA-1273 in preventing SARS-CoV-2 infection, COVID-19 hospitalization, and COVID-19 hospital death by month after index date among immunocompetent adults aged ≥ 50 years, Kaiser Permanente Southern California.
|
4-dose Vaccinated |
3-dose Vaccinated |
Adjustedarelative vaccine effectiveness % (95 % CI) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Outcomes | N | Number of cases | Number of person years |
Incidence per 1000 person-years (95 % CI) |
N | Number of cases | Number of person years |
Incidence per 1000 person-years (95% CI) |
|
| SARS-CoV-2 infection | |||||||||
| 0-<2 months | 178,492 | 5782 | 26,980.3 | 214.3 (208.9–219.9) | 178,492 | 5361 | 16,698.4 | 321.1 (312.6–329.8) | 31.7 (29.1–34.3) |
| 2-<4 months | 135,528 | 4705 | 15,309.6 | 307.3 (298.7–316.2) | 55,598 | 1427 | 4,329.7 | 329.6 (312.9–347.1) | 12.8 (7.3–18.0) |
| 4-<5 monthsb | 40,231 | 278 | 1,033.4 | 269.0 (239.2–302.6) | 4,125 | 16 | 74.9 | 213.6 (130.8–348.6) | −24.9 (-54.8–19.8) |
| COVID-19 hospitalization | |||||||||
| 0-<2 monthsb | 178,492 | 69 | 27,387.0 | 2.5 (2.0–3.2) | 178,492 | 148 | 17,102.8 | 8.7 (7.4–10.2) | 70.3 (60.2–77.8) |
| 2-<4 monthsb | 140,420 | 62 | 16,182.2 | 3.8 (3.0–4.9) | 59,318 | 37 | 4,718.7 | 7.8 (5.7–10.8) | 58.4 (36.7–72.7) |
| 4-<5 monthsb,c | 43,700 | 4 | 1,126.8 | 3.6 (1.3–9.5) | 4,655 | 1 | 84.7 | 11.8 (1.7–83.8) | 68.6 (-65.3–96.6) |
| COVID-19 hospital death | |||||||||
| 0-<2 monthsb,c,d | 178,492 | 1 | 27,392.0 | 0.04 (0.01–0.3) | 178,492 | 4 | 17,113.2 | 0.2 (0.1–0.6) | 85.6 (–23.1–98.4) |
| 2-<4 months | 140,477 | 1 | 16,192.6 | 0.06 (0.01–0.4) | 59,418 | 0 | 4,728.6 | N/A | N/A |
When hazard ratio or its 95 % CI was >1, the rVE or its 95% CI was transformed as ([1/hazard ratio] – 1) × 100.
Abbreviations: CI = confidence interval; COVID-19 = Coronavirus disease 2019; N/A = not applicable; SARS-CoV-2 = severe acute respiratory syndrome coronavirus.
Adjusted for covariates age, sex, race/ethnicity, index date (in months), time between third dose and index date, history of SARS-CoV-2 infection, and medical center area.
Medical center area was removed from adjustment set due to lack of model convergence.
Race/ethnicity and history of SARS-CoV-2 infection removed from adjustment set due to lack of model convergence.
Age and index date (in months) removed from adjustment set due to lack of model convergence.
4. Discussion
This study provides real-world evidence of significant protection conferred by 4 doses of mRNA-1273 against SARS-CoV-2 infection and COVID-19 hospitalization compared to 3 doses in older adults. These findings were consistent across subgroups. Our findings are also consistent with previous studies demonstrating improved protection against COVID-19 outcomes after the fourth dose. A US study among adults aged ≥50 years reported 3- and 4-dose VE of mRNA COVID-19 vaccines against COVID-19 hospitalization to be 55 % and 80 %, respectively [10]. In Canada, the 4-dose VE of mRNA COVID-19 vaccines against symptomatic infection and severe outcomes was 69 % and 86 %, respectively [4]. Studies from Israel among individuals aged ≥60 years reported the 4- vs. 3-dose rVE of BNT162b2 to be 55–65 % against SARS-CoV-2 infection [5], [6], 68 % against COVID-19-related hospitalization, and 74 % against COVID-19-related death [6]. We also observed waning of rVE 2 months after the fourth dose against SARS-CoV-2 infection and COVID-19 hospitalization, consistent with previous studies [5], [8].
Overall, we observed a lower 4- vs. 3- dose rVE compared to our previous studies spanning delta and omicron periods [11]. Lower rVE may be partially explained by antigen test results included in this study; some of our previous studies were limited to samples successfully sequenced by polymerase chain reaction (PCR), potentially indicative of higher viral load and more severe disease. In this study, higher rVE against PCR-confirmed infection (32.6 % [29.2 %,35.9 %]) was observed in a sensitivity analysis. This study also included older populations (≥50 years) only, unlike our previous reports. Further, substantial immune escape from both vaccination- and infection-induced neutralizing antibodies has been reported for BA.2.12.1, BA.4, and BA.5, with lower neutralizing antibody titers as compared to BA.1 and BA.2 [12]. Additionally, recent data on binding and neutralizing antibodies and B-cell and T-cell immunity suggest that prior infection can decrease subsequent immunity [13]. Differential immune imprinting in individuals with immunity against earlier variants could compromise immune responses to omicron subvariants. Such immune modulations may partially explain the lower rVE observed in our study, particularly, the null rVE against SARS-CoV-2 infection 4–5 months after the fourth dose. Lastly, rVE estimates represent additional protection provided by the fourth dose compared to the third dose, and should be interpreted accordingly. Nevertheless, despite the low rVE against SARS-CoV-2 infection (26 %), the rVE against COVID-19 hospitalization remained high.
Our study has several strengths. This was a population-based, real-world study in an integrated health care system with a large, diverse, and stable population. KPSC’s comprehensive EHR enabled accurate capture of exposure, outcomes, and covariates. The matched cohort design increased generalizability to the older US population, unlike test-negative designs, which limit generalizability to those who are tested. We reported rVE of 4 doses vs. 3 doses, as opposed to using unvaccinated individuals as a comparator group, to reduce selection bias. Lastly, we confirmed hospitalizations “for” COVID-19 (rather than “with” a COVID-19 diagnosis) by manual chart review.
Nonetheless, our study has limitations. Due to the observational study design, there may be residual confounding, such as healthcare seeking behaviors. However, since we compared 4-dose vs. 3-dose recipients instead of unvaccinated individuals, we expect such unmeasured confounding to be minimal. Non-differential misclassification of SARS-CoV-2 infection may have occurred due to false positive/negative results or erroneous diagnosis codes. Although we did not evaluate rVE associated with specific variants, this study was conducted during a period of omicron predominance, and most of our cases were likely infected by omicron sublineages. Additionally, it is difficult to make meaningful conclusions from the rVE estimated for the 4–5 month-period after the index date due to limited sample size and short follow-up. Lastly, we only included individuals aged ≥50 years and had a limited sample size for severe outcomes. The fourth dose was authorized in March 2022 for adults aged ≥50 years, and >95 % of fourth dose recipients at KPSC during the study period were ≥50 years of age.
Four doses of mRNA-1273 provided additional protection against SARS-CoV-2 infection and COVID-19 hospitalization compared to 3 doses in individuals aged ≥50 years across various subgroups of demographic/clinical characteristics, although rVE varied and waned over time.
Declaration of Competing Interest
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: JHK, LSS, LQ, BKA, YL, JET, GSL, AF, FX, SQ, and HFT are employees of Kaiser Permanente Southern California, which has been contracted by Moderna to conduct this study. KJB is an adjunct investigator at Kaiser Permanente Southern California. SC was an employee of and shareholder in Moderna, Inc. at the time of the study. CAT was an employee of and a shareholder in Moderna Inc. at the time of analysis conception; CAT is currently an employee of AstraZeneca. JHK received funding from GlaxoSmithKline unrelated to this manuscript. LSS received funding from GlaxoSmithKline and Dynavax unrelated to this manuscript. LQ received funding from GlaxoSmithKline and Dynavax unrelated to this manuscript. BKA received funding from GlaxoSmithKline, Dynavax, Genentech, and Pfizer unrelated to this manuscript. YL received funding from GlaxoSmithKline and Pfizer unrelated to this manuscript. JET received funding from Pfizer unrelated to this manuscript. GSL received funding from GlaxoSmithKline unrelated to this manuscript. AF received funding from Pfizer, GlaxoSmithKline, and Gilead unrelated to this manuscript. KJB received funding from GlaxoSmithKline, Dynavax, Pfizer, and Gilead unrelated to this manuscript. FX received funding from Pfizer, Janssen, and Hologic unrelated to this manuscript. SQ received funding from Dynavax unrelated to this manuscript. HFT received funding from GlaxoSmithKline unrelated to this manuscript; HFT also served on advisory boards for Janssen and Pfizer.
Acknowledgments
Acknowledgements
The authors would like to acknowledge the following Kaiser Permanente Southern California staff: Radha Bathala, Maria Navarro, Elsa Olvera, Joy Gelfond, Jonathan Arguello, Kourtney Kottmann, Joanna Truong, and Diana Romero for their contributions in manual chart review. The authors would also like to acknowledge the contributions by Moderna staff: Julie Vanas. Medical writing and editorial assistance were provided by Jared Mackenzie, PhD, of MEDiSTRAVA in accordance with Good Publication Practice (GPP3) guidelines, funded by Moderna, Inc., and under the direction of the authors. The authors thank the patients of Kaiser Permanente for their partnership with us to improve their health. Their information, collected through our electronic health record systems, leads to findings that help us improve care for our members and can be shared with the larger community.
Funding
This study was supported by Moderna, Inc.
Author contributions
Conceptualization, JHK, LSS, LQ, AF, KJB, CAT, HFT; Acquisition, methodology, analysis, or interpretation of data, JHK, LSS, LQ, BKA, YL, JET, GSL, AF, KJB, FX, SQ, SC, CAT, HFT; Drafting of the manuscript, JHK; Critical revision of the manuscript for important intellectual content, LSS, LQ, BKA, YL, JET, GSL, AF, KJB, FX, SQ, SC, CAT, HFT; Statistical analysis, LQ, YL, JET, SQ; Obtained funding, CAT, HFT; Project administration, LSS, GSL, SC; Supervision, SC, HFT. All authors approved the final version of the manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. The corresponding author (the guarantor) is responsible for the overall content and conduct of the study, and the decision to publish.
Data availability statement
The data presented in this study are not publicly available due to privacy concerns.
Footnotes
Supplementary data to this article can be found online at https://doi.org/10.1016/j.vaccine.2023.06.016.
Appendix A. Supplementary data
The following are the Supplementary data to this article:
Data availability
The data presented in this study are not publicly available due to privacy concerns.
References
- 1.Centers for Disease Control and Prevention. COVID Data Tracker. Available at: https://covid.cdc.gov/covid-data-tracker/#datatracker-home. Accessed 25 January 2023.
- 2.Centers for Disease Control and Prevention. Factors That Affect Your Risk of getting Very Sick from COVID-19. Available at: https://www.cdc.gov/coronavirus/2019-ncov/your-health/risks-getting-very-sick.html. Accessed 29 November 2022.
- 3.United States Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-second-booster-dose-two-covid-19-vaccines-older-and. Accessed 2 December 2022.
- 4.Grewal R., Kitchen S.A., Nguyen L., et al. Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study. BMJ. 2022;378:e071502. doi: 10.1136/bmj-2022-071502. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Gazit S., Saciuk Y., Perez G., Peretz A., Pitzer V.E., Patalon T. Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study. BMJ. 2022;377:e071113. doi: 10.1136/bmj-2022-071113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Magen O., Waxman J.G., Makov-Assif M., et al. Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med. 2022;386(17):1603–1614. doi: 10.1056/NEJMoa2201688. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Centers for Disease Control and Prevention. COVID-19 Vaccinations in the United States. Available at: https://covid.cdc.gov/covid-data-tracker/?utm_source=substack&utm_medium=email#vaccinations_vacc-people-booster-percent-pop5. Accessed 25 January 2023.
- 8.Florea A., Sy L.S., Qian L., et al. Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults. Clin Infect Dis. 2023;76(2):252–262. doi: 10.1093/cid/ciac785. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Malden D.E., Tartof S.Y., Ackerson B.K., et al. Natural Language Processing for Improved Characterization of COVID-19 Symptoms: Observational Study of 350,000 Patients in a Large Integrated Health Care System. JMIR Public Health Surveill. 2022;8(12):e41529. doi: 10.2196/41529. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Link-Gelles R, Levy ME, Gaglani M, et al. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022. MMWR Morb Mortal Wkly Rep 2022; 71(29): 931-9. [DOI] [PMC free article] [PubMed]
- 11.Tseng H.F., Ackerson B.K., Bruxvoort K.J., et al. Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Nat Commun. 2023;14(1):189. doi: 10.1038/s41467-023-35815-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Hachmann N.P., Miller J., Collier A.Y., et al. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med. 2022;387(1):86–88. doi: 10.1056/NEJMc2206576. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Reynolds C.J., Pade C., Gibbons J.M., et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science. 2022;377(6603):eabq1841. doi: 10.1126/science.abq1841. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data presented in this study are not publicly available due to privacy concerns.
The data presented in this study are not publicly available due to privacy concerns.